SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing heavy investor attention as the market anticipates a catalyst-heavy year, featuring three critical Phase 3 data readouts for its lead psychiatry program. While some community members voice concerns over potential share dilution and historical management turnover, bullish sentiment remains centered on the company's strong cash position and the regulatory potential for its novel LSD-based therapy in a massive total addressable market.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are surging following a Bloomberg report that the company is exploring strategic options, including a potential sale to a major media firm. The news has ignited significant community debate, with traders analyzing the stock's newfound momentum, the viability of various buyout candidates, and the potential for a larger breakout as institutional interest grows.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending as the market digests strong trading updates and continued progress on strategic nuclear projects like SMRs, even as investors navigate ongoing volatility from geopolitical tensions in the Middle East. The community is focused on the company's resilient profit outlook and major defense-related contract wins, which are being weighed against broader concerns about fuel costs and global travel demand.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending as investors digest the impact of a 1-for-10 reverse stock split and a strategic shift toward lower-volatility, large-cap holdings intended to stabilize net asset value. Community sentiment remains polarized, with debates centering on whether the revamped portfolio and ongoing weekly distributions can counteract persistent NAV decay versus the risks of further share price erosion.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors weigh strong first-quarter revenue from its Yartemlea launch against technical selling pressure and volatility surrounding potential clinical data readouts. The community is focused on the upcoming EMA regulatory decision and the impact of J-code reimbursement on commercial adoption, while actively debating the stock's valuation relative to its pipeline potential and recent management changes.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is currently a major focus for traders as they anticipate the upcoming Q1 earnings report and critical interim Phase 1 clinical data for its lead candidate, ABCL635. While the community is actively debating the stock's long-term potential versus its history of underperformance, strong institutional accumulation and notable analyst upgrades are driving significant volume and heightened short-interest volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the community debate the legitimacy of a potential peace agreement with Iran and its impact on the stock. Public discourse is heavily focused on critical scrutiny of Trump's diplomatic record and recent events involving his personal branding, while market participants weigh the stock's volatility against the broader political climate.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillow is facing significant downward pressure as investors react to an antitrust lawsuit filed by the FTC and several states over allegations of anti-competitive practices in rental advertising. The community is actively debating the stock's future, with many weighing the impact of legal risks against Zillow's strategic integration of AI and its position as a dominant, profitable leader in the housing market.

Chip

Chip is trending as investors debate its role as a GPU-backed lending protocol amid significant price volatility and ongoing arguments between those betting on its AI infrastructure utility and others calling it a pump-and-dump scheme. The community is actively tracking its protocol fees and loan pipeline while speculating on whether recent price action represents a bear trap or a continued downward trend.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is experiencing significant momentum driven by government-backed ICE funding and the strategic expansion of detention capacity, with the community actively discussing a potential short squeeze fueled by high institutional ownership and speculative long-dated call options. Investors are closely tracking the company's role in federal immigration enforcement and the potential for asset sales or a government-led acquisition to unlock value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential

Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential...

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% on Analyst Upgrade...

HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at HC Wainwright increased their FY2030 EPS estimates for Syndax Pharmaceuticals in a note issued to investors on Friday, May 1st. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of $3...

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1%  - Time to Sell?

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.1% - Should You Sell...

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00

Barclays raised their price target on Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an "overweight" rating in a research note on Friday...

Syndax Pharmaceuticals Q1 Earnings Call Highlights

Syndax Pharmaceuticals (NASDAQ:SNDX) reported first-quarter 2026 results highlighting more than $100 million in combined net sales for its two commercial products, Revuforj and Niktimvo, as the...

Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.59) by...

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of +17.95% and -7.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth

Nuvation Bio (NUVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syndax Pharmaceuticals (SNDX) Expected to Announce Earnings on Thursday

Syndax Pharmaceuticals (NASDAQ:SNDX) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-syndax-pharmaceuticals-inc-stock...

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

SNDXSyndax Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SNDX News